FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gijsbert Veerman

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Living Beings

Disorders

Physiology

Procedures

Co-author Network

Publications

TOP 3
Kees Smid; André Bergman; Paul P Eijk; Gijsbert Veerman; V W T Ruiz van Haperen; Paul van den IJssel; Bauke Ylstra; Godefridus J Peters
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
André Bergman; Paul P Eijk; Veronique Ruiz van Haperen; Kees Smid; Gijsbert Veerman; Isabelle Hubeek; Paul van den IJssel; Bauke Ylstra; Godefridus J Peters
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
André Bergman; HERBERT PINEDO; Iannis Talianidis; Gijsbert Veerman; Willem J P Loves; Clasina L Van der Wilt; Godefridus J Peters
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gijsbert Veerman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Kees Smid; André Bergman; Paul P Eijk; Gijsbert Veerman; V W T Ruiz van Haperen; Paul van den IJssel; Bauke Ylstra; Godefridus J Peters
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Nucleosides, nucleotides & nucleic acids 2006;25(9-11):1001-7.
2005: André Bergman; Paul P Eijk; Veronique Ruiz van Haperen; Kees Smid; Gijsbert Veerman; Isabelle Hubeek; Paul van den IJssel; Bauke Ylstra; Godefridus J Peters
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Cancer research 2005;65(20):9510-6.
2003: André Bergman; HERBERT PINEDO; Iannis Talianidis; Gijsbert Veerman; Willem J P Loves; Clasina L Van der Wilt; Godefridus J Peters
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
British journal of cancer 2003;88(12):1963-70.
2001: André Bergman; B Munch-Petersen; P B Jensen; M Sehested; Gijsbert Veerman; Daphne Voorn; Kees Smid; HERBERT PINEDO; Godefridus J Peters
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Biochemical pharmacology 2001;61(11):1401-8.
2001: Clasina L Van der Wilt; Harold H J Backus; Kees Smid; L Comijn; Gijsbert Veerman; Dorine Wouters; Daphne Voorn; David G Priest; Marlene A Bunni; Fraser Mitchell; Ann L Jackman; Gerrit Jansen; Godefridus J Peters
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
Cancer research 2001;61(9):3675-81.
2000: Catharina J A Van Moorsel; HERBERT PINEDO; Kees Smid; Elizabeth M Comijn; Daphne Voorn; Gijsbert Veerman; B Lakerveld; Wim J F van der Vijgh; Giuseppe Giaccone; Pieter E Postmus; Godefridus J Peters
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2420-9.
2000: Catharina J A Van Moorsel; André Bergman; Gijsbert Veerman; Daphne Voorn; Veronique Ruiz van Haperen; Judith R Kroep; HERBERT PINEDO; Godefridus J Peters
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
Biochimica et biophysica acta 2000;1474(1):5-12.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; André Bergman; CM Kuiper; Jan B Vermorken; Wim J F van der Vijgh; Godefridus J Peters
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
European journal of cancer (Oxford, England : 1990) 1999;35(5):808-14.
1999: Catharina J A Van Moorsel; Judith R Kroep; HERBERT PINEDO; Gijsbert Veerman; Daphne Voorn; Pieter E Postmus; Jan B Vermorken; Cees J van Groeningen; Wim J F van der Vijgh; Godefridus J Peters
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; A Guechev; Kees Smid; Willem J P Loves; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Biochemical pharmacology 1999;57(4):407-15.
1999: André Bergman; HERBERT PINEDO; A P M Jongsma; M Brouwer; Veronique Ruiz van Haperen; Gijsbert Veerman; A Leyva; S Eriksson; Godefridus J Peters
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Biochemical pharmacology 1999;57(4):397-406.
1998: E Smitskamp-Wilms; HERBERT PINEDO; Gijsbert Veerman; Veronique Ruiz van Haperen; Godefridus J Peters
Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
European journal of cancer (Oxford, England : 1990) 1998;34(6):921-6.
1998: Catharina J A Van Moorsel; Gijsbert Veerman; Veronique Ruiz van Haperen; André Bergman; P B Jensen; M Sehested; Godefridus J Peters
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines.
Advances in experimental medicine and biology 1998;431():661-5.
1998: Judith R Kroep; Catharina J A Van Moorsel; Gijsbert Veerman; Daphne Voorn; R M Schultz; J F Worzalla; LEE TANZER; Ronald L Merriman; HERBERT PINEDO; Godefridus J Peters
Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Advances in experimental medicine and biology 1998;431():657-60.
1998: Clasina L Van der Wilt; Kees Smid; Gijsbert Veerman; Godefridus J Peters
The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil.
Advances in experimental medicine and biology 1998;431():653-6.
1998: Veronique Ruiz van Haperen; Gijsbert Veerman; Catharina J A Van Moorsel; Godefridus J Peters
Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Advances in experimental medicine and biology 1998;431():637-40.
1998: André Bergman; HERBERT PINEDO; Gijsbert Veerman; CM Kuiper; Godefridus J Peters
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Advances in experimental medicine and biology 1998;431():591-4.
1998: André Bergman; HERBERT PINEDO; Veronique Ruiz van Haperen; Gijsbert Veerman; CM Kuiper; Godefridus J Peters
Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Advances in experimental medicine and biology 1998;431():587-90.
1998: Catharina J A Van Moorsel; Gijsbert Veerman; Jan B Vermorken; Daphne Voorn; Judith R Kroep; André Bergman; HERBERT PINEDO; Godefridus J Peters
Mechanisms of synergism between gemcitabine and cisplatin.
Advances in experimental medicine and biology 1998;431():581-5.
1997: Catharina J A Van Moorsel; Gijsbert Veerman; André Bergman; A Guechev; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Combination chemotherapy studies with gemcitabine.
Seminars in oncology 1997;24(2 Suppl 7):S7-17-S7-23.
1996: Godefridus J Peters; Veronique Ruiz van Haperen; André Bergman; Gijsbert Veerman; E Smitskamp-Wilms; Catharina J A Van Moorsel; CM Kuiper; Boudewijn J M Braakhuis
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
Seminars in oncology 1996;23(5 Suppl 10):16-24.
1996: V W van Haperen; Gijsbert Veerman; Jan B Vermorken; HERBERT PINEDO; G Peters
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1996;51(7):911-8.
1996: André Bergman; Veronique Ruiz van Haperen; Gijsbert Veerman; CM Kuiper; Godefridus J Peters
Synergistic interaction between cisplatin and gemcitabine in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):521-30.
1996: Gijsbert Veerman; Veronique Ruiz van Haperen; Jan B Vermorken; Paul Noordhuis; Boudewijn J M Braakhuis; HERBERT PINEDO; Godefridus J Peters
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Cancer chemotherapy and pharmacology 1996;38(4):335-42.
1995: Godefridus J Peters; André Bergman; Veronique Ruiz van Haperen; Gijsbert Veerman; CM Kuiper; Boudewijn J M Braakhuis
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Seminars in oncology 1995;22(4 Suppl 11):72-9.
1995: Boudewijn J M Braakhuis; Veronique Ruiz van Haperen; Epie Boven; Gijsbert Veerman; Godefridus J Peters
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Seminars in oncology 1995;22(4 Suppl 11):42-6.
1995: Veronique Ruiz van Haperen; Gijsbert Veerman; S Eriksson; A P Stegmann; Godefridus J Peters
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Seminars in oncology 1995;22(4 Suppl 11):35-41.
1995: M Gielen; Rudolph Willem; A Bouhdid; D De Vos; CM Kuiper; Gijsbert Veerman; G J Peters
In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of five organotin compounds.
In vivo (Athens, Greece) 1995;9(1):59-63.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; Epie Boven; Paul Noordhuis; Jan B Vermorken; Godefridus J Peters
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Biochemical pharmacology 1994;48(7):1327-39.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; S Eriksson; Epie Boven; A P Stegmann; M Hermsen; Jan B Vermorken; HERBERT PINEDO; Godefridus J Peters
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Cancer research 1994;54(15):4138-43.
1994: André Bergman; Veronique Ruiz van Haperen; Gijsbert Veerman; CM Kuiper; Godefridus J Peters
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Advances in experimental medicine and biology 1994;370():139-43.
1993: Veronique Ruiz van Haperen; Gijsbert Veerman; Jan B Vermorken; Godefridus J Peters
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Biochemical pharmacology 1993;46(4):762-6.
1993: Veronique Ruiz van Haperen; Gijsbert Veerman; Boudewijn J M Braakhuis; Jan B Vermorken; Epie Boven; A Leyva; Godefridus J Peters
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2132-7.
1991: Veronique Ruiz van Haperen; Gijsbert Veerman; Paul Noordhuis; Jan B Vermorken; Godefridus J Peters
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Advances in experimental medicine and biology 1991;309A():57-60.